New drug cocktail targets rare eye cancer
NCT ID NCT05524935
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests two drugs—olaparib and pembrolizumab—together in 12 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the disease. The study is active but no longer recruiting, and results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib (Lynparza) and pembrolizumab (Keytruda)
- What this could lead to
- If it works, this combination could offer a new treatment option for advanced uveal melanoma, a rare eye cancer with few effective therapies.
- What could go wrong
- This is a very small early-phase trial (12 people) with no control group. The combination may not shrink tumors or improve survival, and side effects from the drugs could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug tame advanced solid tumors?
- Can a single eye injection shrink melanoma and save sight?
- Supercharged immune cells take aim at childhood cancers
- Can a vaccine keep melanoma from coming back? large trial tests immune boosters
- Can a pill prevent eye cancer spread? new trial aims to find out